IPO & Public Markets

The struggling footwear brand is selling its assets to become NewBird AI, a GPU provider. Is it a visionary gamble or a desperate move in the AI gold rush?

In a major strategic move, Premier Research appoints Paul Spreen as CCO, signaling a bold push to capture the rebounding biotech market.

Avory & Co. enters the crowded ETF market with AVRY, an actively managed fund shunning trends for a concentrated portfolio of high-quality stocks.

Nearly a century old, NPF Investment Advisors launches an actively managed ETF, aiming to deliver tax efficiency and long-term growth to a new generation.

Proem Acquisition Corp I launches a $130M IPO, led by tech IPO guru Imran Khan. But can it succeed in a revived, yet risk-laden, SPAC landscape?

Belgian biotech Agomab Therapeutics secures $200 million in its Nasdaq debut, fueling its mission to develop therapies for debilitating fibrotic conditions.

Pan-European exchange reports a strong start to 2026, fueled by a historic defense IPO and a dramatic spike in foreign exchange and metals trading.

A small-cap food company plans a major NASDAQ leap, but its future hinges on a secret 'clean' technology. Can this ambitious, risky pivot succeed?

Canadian biotech Satellos Bioscience seeks a Nasdaq listing and a $50M public offering to advance its promising muscle regeneration drug for Duchenne.

After a blockbuster IPO raised nearly $300 million, dermatologist-founded Veradermics is poised to challenge the hair loss market with its new oral pill.

NREF's massive capital raise signals strong investor confidence. We dive into what this bold move reveals about the market and income-seeking investors.